180 Life Sciences ROCE
What is the ROCE of 180 Life Sciences?
The ROCE of 180 Life Sciences Corp. is 14,186.55%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with roce similar to 180 Life Sciences
- Blue Apron Inc has ROCE of 5,016.13%
- ParkerVision has ROCE of 5,589.92%
- Asensus Surgical Inc has ROCE of 5,861.92%
- Whiting USA Trust II has ROCE of 7,251.43%
- Astra has ROCE of 7,618.05%
- Kalo Gold has ROCE of 8,333.61%
- 180 Life Sciences has ROCE of 14,186.55%
- Ideanomics Inc has ROCE of 29,881.71%
- Internet Gold - Golden Lines has ROCE of 31,538.46%
- Predictiv Ai Inc has ROCE of 33,476.12%
- T2 Biosystems Inc has ROCE of 56,826.92%
- AMBG has ROCE of 145,496.28%
- Woluwe Shopping Center has ROCE of 520,618,500.00%